Rothschild Asset Management Inc. increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 144.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 840,155 shares of the biopharmaceutical company’s stock after purchasing an additional 496,469 shares during the quarter. Gilead Sciences accounts for about 0.7% of Rothschild Asset Management Inc.’s holdings, making the stock its 21st largest holding. Rothschild Asset Management Inc. owned 0.06% of Gilead Sciences worth $68,069,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Keel Point LLC grew its position in shares of Gilead Sciences by 0.4% in the second quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock valued at $221,000 after purchasing an additional 12 shares in the last quarter. Paradigm Financial Advisors LLC grew its position in shares of Gilead Sciences by 0.3% in the second quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock valued at $617,000 after purchasing an additional 26 shares in the last quarter. Princeton Portfolio Strategies Group LLC grew its position in shares of Gilead Sciences by 0.4% in the second quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock valued at $691,000 after purchasing an additional 41 shares in the last quarter. Arrow Financial Corp grew its position in shares of Gilead Sciences by 0.3% in the second quarter. Arrow Financial Corp now owns 17,771 shares of the biopharmaceutical company’s stock valued at $1,258,000 after purchasing an additional 45 shares in the last quarter. Finally, Auxier Asset Management grew its position in shares of Gilead Sciences by 1.4% in the second quarter. Auxier Asset Management now owns 6,773 shares of the biopharmaceutical company’s stock valued at $479,000 after purchasing an additional 96 shares in the last quarter. 76.47% of the stock is owned by institutional investors.
In other Gilead Sciences news, insider John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $73.62, for a total value of $3,681,000.00. Following the sale, the insider now owns 3,046,766 shares of the company’s stock, valued at approximately $224,302,912.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $74.64, for a total value of $1,119,600.00. Following the completion of the sale, the executive vice president now directly owns 70,988 shares in the company, valued at approximately $5,298,544.32. The disclosure for this sale can be found here. Insiders sold a total of 358,333 shares of company stock worth $28,066,908 in the last ninety days. 1.30% of the stock is owned by corporate insiders.
Gilead Sciences, Inc. (NASDAQ:GILD) traded up $0.82 during midday trading on Monday, hitting $80.14. The company had a trading volume of 9,972,064 shares, compared to its average volume of 9,910,000. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.48 and a current ratio of 3.55. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $89.54. The stock has a market capitalization of $104,660.00, a price-to-earnings ratio of 23.03, a P/E/G ratio of -1.77 and a beta of 1.22.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The firm had revenue of $5.95 billion for the quarter, compared to analyst estimates of $5.71 billion. During the same quarter last year, the company posted $2.70 earnings per share. The business’s revenue was down 18.7% on a year-over-year basis. equities analysts forecast that Gilead Sciences, Inc. will post 6.41 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be issued a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 2.85%. The ex-dividend date of this dividend is Thursday, March 15th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s payout ratio is currently 59.77%.
Several research analysts recently weighed in on GILD shares. Berenberg Bank set a $96.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research report on Thursday, October 19th. JPMorgan Chase & Co. set a $85.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Credit Suisse Group reiterated a “buy” rating and issued a $82.00 price objective on shares of Gilead Sciences in a research report on Thursday, December 7th. Zacks Investment Research lowered Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, December 27th. Finally, ValuEngine upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. Gilead Sciences has an average rating of “Buy” and a consensus target price of $87.04.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.